...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochimica et biophysica acta. Reviews on cancer >RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy
【24h】

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

机译：胰腺导管腺癌中的ron受体酪氨酸激酶：治疗恶性肿瘤和药物靶标的病原机制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with poor prognosis and high mortality. Molecular aberrations associated with PDAC pathogenesis and progression have been extensively investigated. Nevertheless, these findings have not been translated into clinical practice. Lack of therapeutics for PDAC treatment is another challenge. Recent application of molecularly targeted and immunoregulatory therapies appears to be disappointing. Thus, discovery of new targets and therapeutics is urgently needed to combat this malignant disease. The RON receptor tyrosine kinase is a tumorigenic determinant in PDAC malignancy, which provides the rationale to target RON for PDAC treatment. In this review, we summarize the latest evidence of RON in PDAC pathogenesis and the development of anti-RON antibody-drug conjugates for potential PDAC therapy. The finding that anti-RON antibody-drug conjugates show efficacy in preclinical animal models highlights the potential of this novel class of anti-cancer biotherapeutics in future clinical trials.
机译：胰腺导管腺癌（PDAC）是最具侵略性的癌症之一，预后差和高死亡率。广泛研究了与PDAC发病机制和进展相关的分子像差。然而，这些发现尚未翻译成临床实践。 PDAC治疗缺乏治疗方法是另一个挑战。最近的分子靶向和免疫调节疗法的应用似乎令人失望。因此，迫切需要发现新的目标和治疗方法来打击这种恶性疾病。 Ron受体酪氨酸激酶是PDAC恶性肿瘤中的致瘤决定因素，其为PDAC治疗提供了靶向RON的理由。在这篇综述中，我们总结了PDAC发病机制中RON的最新证据以及用于潜在的PDAC治疗的抗RON抗体 - 药物缀合物的发育。发现抗RON抗体 - 药物缀合物在临床前动物模型中表现出疗效的结果突出了这种新型抗癌生物治疗剂在未来的临床试验中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号